In addition, the anti-VISTA treatment also resulted in an enhanced percentage of granzyme B+ Perforin+ CD8+ T cells compared to isotype control in the majority of ccRCC patients (data not shown). This evidence concerns the gene PRF1 and nonpapillary renal cell carcinoma.